A whopping 80 percent of enterprises are investing today in AI, but one in three business leaders believe their company will need to invest more over the next 36 months to keep pace with competitors. At the same time, enterprises are anticipating significant barriers to adoption and are looking to strategize against those issues by creating a new C-suite position, the Chief AI Officer (CAIO), to streamline and coordinate AI adoption. These results come from a survey of 260 large organizations that operate globally, conducted by leading technology industry market research firm Vanson Bourne on behalf of Teradata (NYSE: TDC), the leading data and analytics company.
“There is an important trend emerging evident in this report — enterprises today see AI as a strategic priority that will help them outpace the competition in their respective industries,” says Atif Kureishy, Vice President, Emerging Practices at Think Big Analytics, a Teradata company. “But to leverage the full potential of this technology and gain maximum ROI, these businesses will need to revamp their core strategies so AI has an embedded role from the data center to the boardroom.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8075951-teradata-state-of-artificial-intelligence-ai-for-enterprises/
Concentrix Corporation is expanding its Tempe, Arizona, presence and opening a new flagship global services delivery center to keep pace with its rapid growth from both new and existing clients. Concentrix will deliver its high-value business services from their new state-of-the-art facility, and will continue to draw upon the talented labor pool available in the Phoenix Valley.
Concentrix partners with its clients to deliver end-to-end customer engagement services, technology innovations, analytics, process optimization, and business improvements. Concentrix transforms the customer experience, and streamlines front and back office and industry-specific processes to provide the highest value from every customer interaction.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7318551-concentrix-corporation-launches-flagship-global-delivery-center-tempe-arizona/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
Work intensity among European workers is still high, and it has not increased over the past five years, according to the first findings of the 5th European Working Conditions Survey, out today.
The survey also found that for most workers (67%), the pace of work is set by direct demands from people and working at high speeds remains high. The extent to which workers can make their own decisions about how they do their job has not improved, leaving a large number of workers ill-equipped to deal with work’s demands. European workers also remain as exposed to physical hazards, however, as they did 20 years ago.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/eurofound/46312/
http://www.dualfit.com - This 5 step plyometric cardio circuit is great for burning a serious amount of calories and developing explosive muscles!
Check out Steve's site for more workouts like this:
- http://www.pfitpfun.com
- http://www.dobcx.com
Training Style:
Pyometrics, also known as jump training or plyos
Tools:
Dumbbells or Barbell, pull up bar or pull down cable/band, and box or bench
Training Tips:
Plyometric training, primarily used for athletes not only improves strength, power and stamina, it burns a serious amount of calories too. Watch the training video to reference ideal pace and intensity so you get the most out of this workout. In this circuit, each plyometric movement is followed by a strength movement to help improve both conditioning and muscle tone all in one workout. Plyometric exercises should be explosive and powerful. Rest should be limited.
